Mercado europeo de detección de alto contenido, por tipo de producto (instrumentos, consumibles, software, servicios y accesorios), aplicación (detección primaria y secundaria, identificación y validación de objetivos, estudios de toxicidad, elaboración de perfiles de compuestos y otras aplicaciones), tecnología (microscopía, citometría de flujo , inmunohistoquímica, matriz extracelular basada en andamios, ELISA, Western Blot y otros), usuario final (empresas farmacéuticas y de biotecnología, organizaciones de investigación por contrato, laboratorios, institutos académicos y gubernamentales, otros), canal de distribución (licitaciones directas, ventas minoristas) - Tendencias de la industria y pronóstico hasta 2030.
Análisis y perspectivas del mercado de cribado de alto contenido en Europa
La creciente adopción de HCS en actividades de investigación como el análisis basado en células y el descubrimiento de fármacos ha aumentado la demanda del mercado. Las crecientes iniciativas gubernamentales y la financiación para el descubrimiento de fármacos y los programas de investigación relacionados también contribuyen al crecimiento del mercado. Los principales actores del mercado se centran en varios lanzamientos y aprobaciones de servicios durante este período crucial. Además, el aumento en el avance mejorado de las técnicas de imagen y la inteligencia artificial con sistemas HCS también contribuye a la creciente demanda de HCS.
Se espera que el mercado crezca en el año de pronóstico debido al aumento en el número de actores del mercado y la disponibilidad de equipos HCS de tecnología avanzada. Junto con esto, los fabricantes están involucrados en la actividad de desarrollo para lanzar sistemas HCS avanzados, novedosos y eficientes. Se espera que el creciente desarrollo en el campo de las técnicas avanzadas impulse aún más el crecimiento del mercado. Sin embargo, se espera que dificultades como las estrictas regulaciones para la producción y comercialización de productos HCS frenen el crecimiento del mercado.
Data Bridge Market Research analiza que se espera que el mercado europeo de detección de alto contenido alcance un valor de USD 1.057.169,94 mil para 2030, con una CAGR del 6,8% durante el período de pronóstico de 2023-2030.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Personalizable para 2015-2020) |
|
Unidades cuantitativas |
Ingresos en miles de USD |
|
Segmentos cubiertos |
Tipo de producto (instrumentos, consumibles, software, servicios y accesorios), aplicación (cribado primario y secundario, identificación y validación de objetivos, estudios de toxicidad, elaboración de perfiles de compuestos y otras aplicaciones), tecnología ( microscopía , citometría de flujo, inmunohistoquímica, matrices extracelulares, ELISA, transferencia Western y otras), usuario final (empresas farmacéuticas y biotecnológicas, organizaciones de investigación por contrato, laboratorios, institutos académicos y gubernamentales, otros), canal de distribución (licitaciones directas, ventas minoristas) |
|
Países cubiertos |
Alemania, Francia, Reino Unido, Italia, España, Rusia, Turquía, Bélgica, Dinamarca, Países Bajos, Suiza, Suecia, Polonia, Noruega, Finlandia y resto de Europa. |
|
Actores del mercado cubiertos |
BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Subsidiaria de Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. y entre otros. |
Definición del mercado europeo de cribado de alto contenido
El cribado de alto contenido (HCS), también conocido como análisis de alto contenido (HCA), es un enfoque de la biología celular que combina imágenes automatizadas y análisis de datos cuantitativos en un formato de alto rendimiento adecuado para aplicaciones a gran escala, como el descubrimiento de fármacos y la biología de sistemas.
Este mercado se refiere al sector de la industria de las ciencias de la vida que se centra en el uso de técnicas avanzadas de imágenes y análisis para estudiar y analizar procesos celulares y fenómenos biológicos a gran escala. HCS implica la obtención de imágenes automatizadas y el análisis cuantitativo de células u organismos utilizando tecnologías como la microscopía de fluorescencia, el manejo automatizado de líquidos y un sofisticado software de análisis de imágenes.
Dinámica del mercado de cribado de alto contenido en Europa
En esta sección se aborda la comprensión de los factores impulsores, las ventajas, las oportunidades, las limitaciones y los desafíos del mercado. Todo esto se analiza en detalle a continuación:
Conductor
- Avances en las tecnologías de imágenes utilizadas para el cribado de alto contenido
Las tecnologías de obtención de imágenes han estado a la vanguardia del cribado de alto contenido (HCS), lo que permite a los investigadores visualizar y analizar los procesos celulares con un nivel de detalle y una precisión sin precedentes. Además de la obtención de imágenes de alta resolución, se han producido mejoras significativas en la velocidad y el rendimiento de la obtención de imágenes. El HCS ayuda a analizar una gran cantidad de muestras, a menudo en formatos de alto rendimiento. Las tecnologías de obtención de imágenes han evolucionado para proporcionar tiempos de adquisición más rápidos, lo que permite a los investigadores analizar grandes conjuntos de datos en un período más corto. Las técnicas de obtención de imágenes de alta velocidad, como la microscopía confocal de disco giratorio y la microscopía de lámina de luz, permiten una adquisición rápida de imágenes sin comprometer la calidad de la imagen, lo que facilita flujos de trabajo de cribado y análisis de datos eficientes.
A lo largo de los años, se han logrado avances significativos en las modalidades de imágenes, técnicas de microscopía y herramientas de análisis de imágenes, transformando el panorama de HCS e impulsando su expansión en el mercado.
Oportunidad
- Aumento de la integración de la inteligencia artificial y el aprendizaje automático en el descubrimiento y desarrollo de fármacos
Las técnicas de IA, como el aprendizaje automático y el aprendizaje profundo , pueden analizar grandes volúmenes de datos generados en los procesos de descubrimiento y desarrollo de fármacos. Al procesar diversos conjuntos de datos, incluidos datos de HTS, bases de datos químicas y biológicas y datos de ensayos clínicos, los algoritmos de IA pueden identificar patrones, relaciones y tendencias que pueden no ser fácilmente evidentes para los investigadores humanos. Esto puede ayudar a acelerar la identificación de posibles candidatos a fármacos y optimizar el proceso de descubrimiento de fármacos.
La ciencia de datos y la inteligencia artificial son cada vez más importantes en el descubrimiento y desarrollo de fármacos. Además de generar nuevos tratamientos, la inteligencia artificial acelera el trabajo de los equipos clínicos y de descubrimiento de fármacos existentes, ayudándolos a tomar decisiones de investigación fundamentadas y muy precisas.
Por lo tanto, la integración de la IA en el descubrimiento y desarrollo de fármacos tiene el potencial de acelerar el proceso, mejorar las tasas de éxito y reducir los costos, lo que se espera que cree una oportunidad para el crecimiento del mercado.
Restricciones /Desafíos
- Complejidad asociada a muestras celulares y moleculares
Las muestras celulares y moleculares son inherentemente complejas y constan de múltiples componentes celulares, vías de señalización intrincadas e interacciones moleculares dinámicas. Analizar dicha complejidad requiere técnicas de imagen avanzadas, reactivos especializados y algoritmos sofisticados para capturar e interpretar los datos con precisión. La complejidad asociada con las muestras celulares y moleculares presenta un desafío significativo, que se espera que limite el crecimiento del mercado.
- Falta de profesionales capacitados y certificados para operar HCS
La falta de profesionales capacitados y competentes en el manejo de sistemas HCS puede limitar la adopción y utilización de estas tecnologías. Las organizaciones pueden dudar en invertir en plataformas HCS si no cuentan con el personal necesario para operar y mantener eficazmente los equipos.
El HCS requiere experiencia en el manejo de sistemas de imágenes complejos, software de análisis de datos y optimización de ensayos. Los operadores inexpertos pueden tener dificultades para optimizar los protocolos, lo que genera un rendimiento subóptimo y resultados comprometidos. Los profesionales capacitados son cruciales para obtener datos confiables y de alta calidad de los ensayos HCS. Por lo tanto, se espera que la falta de profesionales capacitados y certificados para operar HCS represente un desafío para el crecimiento del mercado.
Acontecimientos recientes
- En enero de 2023, Axion BioSystems anunció la incorporación de Omni Pro 12 a la familia de productos de imágenes de células vivas Omni. La nueva plataforma, que cuenta con robótica integrada y múltiples diseños compatibles con cualquier incubadora estándar, ofrece mayor flexibilidad y eficiencia a los científicos y desarrolladores de fármacos que realizan experimentos de imágenes de células vivas. Este avance en la técnica de imágenes ayudaría a que el descubrimiento de fármacos sea eficiente al contar con experimentos de imágenes de células vivas.
- En diciembre de 2019, Olympus anunció el lanzamiento en EE. UU. de la estación HCS scanR, una solución de imágenes celulares que utiliza inteligencia artificial (IA) para permitir la investigación biológica de próxima generación. Combina la modularidad y flexibilidad de una configuración basada en microscopio con la automatización, velocidad, rendimiento y reproducibilidad de una estación HCS. La tecnología de microscopía de autoaprendizaje de Olympus reduce el fotoblanqueo y mejora la velocidad de adquisición, la sensibilidad de la medición y la precisión, lo que facilita observaciones más prolongadas con una influencia reducida en la viabilidad celular.
Alcance del mercado de cribado de alto contenido en Europa
El mercado europeo de cribado de alto contenido se divide en cinco segmentos importantes según el tipo de producto, la aplicación, la tecnología, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y las diferencias en sus mercados objetivo.
Tipo de producto
- Instrumentos
- Consumibles
- Software
- Servicios
- Accesorios
Según el tipo de producto, el mercado se segmenta en instrumentos, consumibles, software, servicios y accesorios.
Solicitud
- Detección primaria y secundaria
- Identificación y validación de objetivos
- Estudios de toxicidad
- Perfiles compuestos
- Otros
Sobre la base de la aplicación, el mercado está segmentado en detección primaria y secundaria, identificación y validación de objetivos, estudios de toxicidad, perfiles de compuestos y otros.
Tecnología
- Microscopía
- Citometría de flujo
- Andamiaje basado en matriz extracelular
- Western Blot (transferencia Western)
- Prueba ELISA
- Inmunohistoquímica
- Otros
Sobre la base de la tecnología, el mercado está segmentado en microscopía, citometría de flujo, andamiaje basado en matriz extracelular, Western blot, ELISA, inmunohistoquímica y otros.
Usuario final
- Empresas farmacéuticas y biotecnológicas
- Institutos académicos y gubernamentales
- Organizaciones de investigación por contrato
- Laboratorios
- Otros
Sobre la base del usuario final, el mercado está segmentado en empresas farmacéuticas y de biotecnología, institutos académicos y gubernamentales, organizaciones de investigación por contrato, laboratorios y otros.
Canal de distribución
- Licitaciones directas
- Ventas al por menor
Sobre la base del canal de distribución, el mercado se segmenta en licitaciones directas y ventas minoristas .
Análisis y perspectivas regionales del mercado de cribado de alto contenido en Europa
El mercado europeo de cribado de alto contenido se clasifica en cinco segmentos notables según el tipo de producto, la aplicación, la tecnología, el usuario final y el canal de distribución.
Los países cubiertos en este informe de mercado son Alemania, Francia, Reino Unido, Italia, España, Rusia, Turquía, Bélgica, Dinamarca, Países Bajos, Suiza, Suecia, Polonia, Noruega, Finlandia y el resto de Europa.
Se espera que Alemania domine la región europea debido a la creciente inversión en detección de alto contenido y la creciente demanda de los mercados emergentes y la expansión, lo que se espera que impulse el crecimiento del mercado.
La sección de países del informe también proporciona factores de impacto individuales en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, se consideran la presencia y disponibilidad de marcas europeas y los desafíos que enfrentan debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de la proyección de alto contenido en Europa
El panorama competitivo del mercado europeo de cribado de alto contenido proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y el alcance de los productos, el dominio de las aplicaciones y la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado europeo de cribado de alto contenido.
Algunos de los principales actores del mercado que operan en el mercado de cribado de alto contenido en Europa son BD, Merck KGaA, Corning Incorporated, Carl Zeiss AG, Sartorius AG, Zifo RnD Solutions, Axxam SpA, Molecular Devices, LLC. (Subsidiaria de Danaher Corporation), Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Yokogawa Electric Corporation, Sysmex Corporation, Genedata AG, Miltenyi Biotec, Aligned Genetics, Inc. y entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE HIGH CONTENT SCREENING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EUROPE HIGH CONTENT SCREENING MARKET: REGULATIONS
6 MARKET OVERVIEW, EUROPE HIGH CONTENT SCREENING MARKET
6.1 DRIVERS
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES
6.3 OPPORTUNITIES
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D
6.4 CHALLENGES
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS
7 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM
7.2.1.1 FIXED
7.2.1.2 MOBILE
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM
7.2.2.1 FIXED
7.2.2.2 MOBILE
7.2.3 FLOW CYTOMETRY
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR
7.2.5 MICROPLATE MOVER
7.2.6 OTHERS
7.3 SOFTWARE
7.4 CONSUMABLES
7.4.1 REAGENTS & ASSAY KITS
7.4.2 MICROPLATES
7.4.3 OTHERS
7.5 ACCESSORIES
7.6 SERVICES
8 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 PRIMARY AND SECONDARY SCREENING
8.2.1 INSTRUMENTS
8.2.2 CONSUMABLES
8.2.3 ACCESSORIES
8.2.4 SERVICES
8.3 TARGET IDENTIFICATION AND VALIDATION
8.3.1 INSTRUMENTS
8.3.2 CONSUMABLES
8.3.3 ACCESSORIES
8.3.4 SERVICES
8.4 TOXICITY STUDIES
8.4.1 INSTRUMENTS
8.4.2 CONSUMABLES
8.4.3 ACCESSORIES
8.4.4 SERVICES
8.5 COMPOUND PROFILING
8.5.1 INSTRUMENTS
8.5.2 CONSUMABLES
8.5.3 ACCESSORIES
8.5.4 SERVICES
8.6 OTHER APPLICATIONS
9 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 MICROSCOPY
9.3 FLOW CYTOMETRY
9.4 IMMUNOHISTOCHEMISTRY
9.5 MASS SPECTROMETRY
9.6 ELISA
9.7 WESTERN BLOTTING
9.8 OTHERS
9.8.1 3D CELL CULTURE MODEL
9.8.1.1 STEROIDS
9.8.1.2 ORGANOIDS
9.8.1.3 TISSUE ON A CHIP
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD
10 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.2.1 INSTRUMENTS
10.2.2 CONSUMABLES
10.2.3 ACCESSORIES
10.2.4 SERVICES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.3.1 INSTRUMENTS
10.3.2 CONSUMABLES
10.3.3 ACCESSORIES
10.3.4 SERVICES
10.4 LABORATORIES
10.4.1 INSTRUMENTS
10.4.2 CONSUMABLES
10.4.3 ACCESSORIES
10.4.4 SERVICES
10.5 ACADEMIC AND GOVERNMENT INSTITUTES
10.5.1 INSTRUMENTS
10.5.2 CONSUMABLES
10.5.3 ACCESSORIES
10.5.4 SERVICES
10.6 OTHERS
11 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
12 EUROPE HIGH CONTENT SCREENING MARKET, BY REGION
12.1 OVERVIEW
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 RUSSIA
12.1.7 TURKEY
12.1.8 BELGIUM
12.1.9 DENMARK
12.1.10 NETHERLANDS
12.1.11 SWITZERLAND
12.1.12 SWEDEN
12.1.13 POLAND
12.1.14 NORWAY
12.1.15 FINLAND
12.1.16 REST OF EUROPE
13 EUROPE HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 EUROPE CONTENT SCREENING MARKET, COMPANY PROFILES
14.1 THERMO FISHER SCIENTIFIC INC. (2022)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 PERKINELMER INC. (2022)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 YOKOGAWA ELECTRIC CORPORATION (2022)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 BD
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENTS
14.6 MERCK KGAA
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 AGILENT TECHNOLOGIES, INC. (2022)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ALIGNED GENETICS, INC. (2022)
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 AXXAM S.P.A.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIO-RAD LABORATORIES, INC. (2022)
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 CARL ZEISS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CORNING INCORPORATED
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GENEDATA AG
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILTENYI BIOTEC
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 SARTORIUS AG
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 SYSMEX CORPORATION
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 ZIFO RND SOLUTIONS
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tablas
TABLE 1 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE HIGH-CONTENT AND SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE HIGH CONTENT SCREENING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 GERMANY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GERMANY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 GERMANY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 26 GERMANY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 GERMANY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 29 GERMANY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 GERMANY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 32 GERMANY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 34 GERMANY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 35 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 37 GERMANY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 GERMANY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 FRANCE HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 FRANCE CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 46 FRANCE PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 47 FRANCE TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 FRANCE COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 FRANCE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 52 FRANCE 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 53 FRANCE HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 FRANCE LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 FRANCE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 59 U.K. HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.K. INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.K. CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.K. HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 U.K. CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 64 U.K. HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 65 U.K. PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 66 U.K. TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 70 U.K. OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 71 U.K. 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 73 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 U.K. CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 U.K. ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.K. HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 78 ITALY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 ITALY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 ITALY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 ITALY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 ITALY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 ITALY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 84 ITALY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 ITALY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 ITALY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 ITALY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 ITALY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 89 ITALY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 90 ITALY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 91 ITALY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 92 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 ITALY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 97 SPAIN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 SPAIN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 SPAIN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 SPAIN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 SPAIN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 102 SPAIN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 103 SPAIN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 SPAIN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 SPAIN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 106 SPAIN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 SPAIN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 108 SPAIN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 109 SPAIN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 110 SPAIN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 111 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 SPAIN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 SPAIN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 SPAIN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 RUSSIA HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 RUSSIA INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 RUSSIA CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 RUSSIA HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 RUSSIA CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 121 RUSSIA HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 122 RUSSIA PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 RUSSIA TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 RUSSIA TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 RUSSIA COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 RUSSIA HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 127 RUSSIA OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 128 RUSSIA 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 129 RUSSIA HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 130 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 RUSSIA LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 RUSSIA ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 RUSSIA HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 135 TURKEY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 TURKEY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 137 TURKEY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 TURKEY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 TURKEY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 TURKEY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 141 TURKEY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 TURKEY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 143 TURKEY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 144 TURKEY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 TURKEY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 146 TURKEY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 147 TURKEY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 TURKEY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 TURKEY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 154 BELGIUM HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 BELGIUM INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 BELGIUM CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BELGIUM HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 BELGIUM CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 BELGIUM HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 160 BELGIUM PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 161 BELGIUM TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 BELGIUM TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 BELGIUM COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 168 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 169 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 173 DENMARK HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 DENMARK INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 DENMARK CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 DENMARK HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 DENMARK CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 178 DENMARK HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 179 DENMARK PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 180 DENMARK TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 181 DENMARK TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 DENMARK COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 DENMARK HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 184 DENMARK OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 185 DENMARK 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 186 DENMARK HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 187 DENMARK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 DENMARK CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 DENMARK LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 DENMARK ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 DENMARK HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 192 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 NETHERLANDS INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 NETHERLANDS CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 NETHERLANDS HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 NETHERLANDS CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 197 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 198 NETHERLANDS PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 NETHERLANDS TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 NETHERLANDS TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 201 NETHERLANDS COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 203 NETHERLANDS OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 204 NETHERLANDS 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 205 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 206 NETHERLANDS PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 207 NETHERLANDS CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 NETHERLANDS LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 NETHERLANDS ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 210 NETHERLANDS HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 211 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 212 SWITZERLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 213 SWITZERLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 SWITZERLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 SWITZERLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 217 SWITZERLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 218 SWITZERLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 SWITZERLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 SWITZERLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 222 SWITZERLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 223 SWITZERLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 224 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 225 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 SWITZERLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 228 SWITZERLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 229 SWITZERLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 230 SWEDEN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 SWEDEN INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 SWEDEN CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 233 SWEDEN HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 SWEDEN CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 SWEDEN HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 236 SWEDEN PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 SWEDEN TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 SWEDEN TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 239 SWEDEN COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 240 SWEDEN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 241 SWEDEN OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 242 SWEDEN 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 243 SWEDEN HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 244 SWEDEN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 SWEDEN CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 SWEDEN LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 SWEDEN ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 SWEDEN HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 249 POLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 250 POLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 POLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 POLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 POLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 POLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 POLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 256 POLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 257 POLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 258 POLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 POLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 260 POLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 261 POLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 262 POLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 263 POLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 POLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 265 POLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 266 POLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 POLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 268 NORWAY HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 NORWAY INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 270 NORWAY CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 271 NORWAY HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 272 NORWAY CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 273 NORWAY HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 274 NORWAY PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 NORWAY TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 276 NORWAY TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 277 NORWAY COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 NORWAY HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 279 NORWAY OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 280 NORWAY 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 281 NORWAY HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 282 NORWAY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 NORWAY CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 NORWAY LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 285 NORWAY ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 NORWAY HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 287 FINLAND HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 FINLAND INSTRUMENTS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 289 FINLAND CELL IMAGING AND ANALYSIS SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 290 FINLAND HIGH-CONTENT SCREENING SYSTEM IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 FINLAND CONSUMABLES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 292 FINLAND HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 293 FINLAND PRIMARY AND SECONDARY SCREENING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 FINLAND TARGET IDENTIFICATION & VALIDATION IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 FINLAND TOXICITY STUDIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 FINLAND COMPOUND PROFILING IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 297 FINLAND HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 298 FINLAND OTHERS IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 299 FINLAND 3D CELL CULTURE MODEL IN HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY, 2021-2030 (USD THOUSAND)
TABLE 300 FINLAND HIGH CONTENT SCREENING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 301 FINLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 FINLAND CONTRACT RESEARCH ORGANIZATIONS IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 303 FINLAND LABORATORIES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 FINLAND ACADEMIC AND GOVERNMENT INSTITUTES IN HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
TABLE 305 FINLAND HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 306 REST OF EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND)
Lista de figuras
FIGURE 1 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 2 EUROPE HIGH CONTENT SCREENING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HIGH CONTENT SCREENING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HIGH CONTENT SCREENING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HIGH CONTENT SCREENING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HIGH CONTENT SCREENING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HIGH CONTENT SCREENING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HIGH CONTENT SCREENING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HIGH CONTENT SCREENING MARKET: SEGMENTATION
FIGURE 11 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH-CONTENT SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE HIGH CONTENT SCREENING MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HIGH CONTENT SCREENING MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE HIGH CONTENT SCREENING MARKET
FIGURE 14 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2022
FIGURE 19 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 EUROPE HIGH CONTENT SCREENING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2022
FIGURE 23 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 25 EUROPE HIGH CONTENT SCREENING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2022
FIGURE 27 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE HIGH CONTENT SCREENING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 EUROPE HIGH CONTENT SCREENING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE HIGH CONTENT SCREENING MARKET: SNAPSHOT (2022)
FIGURE 35 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022)
FIGURE 36 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 EUROPE HIGH CONTENT SCREENING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 EUROPE HIGH CONTENT SCREENING MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 39 EUROPE HIGH CONTENT SCREENING MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
